- Home
- BEAT vs SNTI Comparison
BEAT vs SNTI Comparison
Compare BEAT & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAT
- SNTI
- Stock Information
- Founded
- BEAT 2015
- SNTI 2016
- Country
- BEAT United States
- SNTI United States
- Employees
- BEAT N/A
- SNTI N/A
- Industry
- BEAT Retail: Computer Software & Peripheral Equipment
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- BEAT Technology
- SNTI Health Care
- Exchange
- BEAT Nasdaq
- SNTI Nasdaq
- Market Cap
- BEAT 37.7M
- SNTI 39.6M
- IPO Year
- BEAT 2021
- SNTI N/A
- Fundamental
- Price
- BEAT $1.41
- SNTI $1.37
- Analyst Decision
- BEAT Buy
- SNTI Strong Buy
- Analyst Count
- BEAT 1
- SNTI 2
- Target Price
- BEAT $8.00
- SNTI $8.50
- AVG Volume (30 Days)
- BEAT 78.2K
- SNTI 120.0K
- Earning Date
- BEAT 11-06-2025
- SNTI 11-13-2025
- Dividend Yield
- BEAT N/A
- SNTI N/A
- EPS Growth
- BEAT N/A
- SNTI N/A
- EPS
- BEAT N/A
- SNTI N/A
- Revenue
- BEAT N/A
- SNTI N/A
- Revenue This Year
- BEAT N/A
- SNTI N/A
- Revenue Next Year
- BEAT $19.35
- SNTI $150.00
- P/E Ratio
- BEAT N/A
- SNTI N/A
- Revenue Growth
- BEAT N/A
- SNTI N/A
- 52 Week Low
- BEAT $0.91
- SNTI $1.26
- 52 Week High
- BEAT $3.48
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- BEAT 59.24
- SNTI 37.01
- Support Level
- BEAT $1.30
- SNTI $1.33
- Resistance Level
- BEAT $1.39
- SNTI $1.39
- Average True Range (ATR)
- BEAT 0.11
- SNTI 0.08
- MACD
- BEAT 0.01
- SNTI 0.01
- Stochastic Oscillator
- BEAT 61.05
- SNTI 31.43
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.